Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 61

1.

Hypercalcemia and acute renal failure associated with calcium carbonate consumption in a patient with hypoparathyroidism.

Mitrogianni Z, Tsimihodimos V, Tzavella E, Elisaf M.

Arch Med Sci. 2014 Dec 22;10(6):1255-7. doi: 10.5114/aoms.2014.47835. No abstract available.

2.

Rationale, design and baseline patient characteristics of the optimal type 2 diabetes management including benchmarking and standard treatment study in Greece.

Kostapanos MS, Tsimihodimos V, Elisaf MS, Tzouvelekis E, Nikas N.

World J Diabetes. 2014 Feb 15;5(1):76-83. doi: 10.4239/wjd.v5.i1.76.

3.

Summarizing the FIELD study: lessons from a 'negative' trial.

Tsimihodimos V, Mikhailidis DP, Elisaf M.

Expert Opin Pharmacother. 2013 Dec;14(18):2601-10. doi: 10.1517/14656566.2013.850075. Epub 2013 Nov 9. Review.

PMID:
24206060
4.

Small high-density lipoprotein (HDL) subclasses are increased with decreased activity of HDL-associated phospholipase A₂ in subjects with prediabetes.

Filippatos TD, Rizos EC, Tsimihodimos V, Gazi IF, Tselepis AD, Elisaf MS.

Lipids. 2013 Jun;48(6):547-55. doi: 10.1007/s11745-013-3787-1. Epub 2013 Apr 2.

PMID:
23546765
5.

Effects of 12 months of treatment with disease-modifying anti-rheumatic drugs on low and high density lipoprotein subclass distribution in patients with early rheumatoid arthritis: a pilot study.

Filippatos TD, Derdemezis CS, Voulgari PV, Tsimihodimos V, Elisaf MS, Tselepis AD, Drosos AA.

Scand J Rheumatol. 2013;42(3):169-75. doi: 10.3109/03009742.2012.745013. Epub 2013 Jan 14.

PMID:
23311768
6.

How should we treat hypertension and dyslipidemia in patients with prediabetes?

Tsimihodimos V, Florentin M, Elisaf MS.

Curr Pharm Des. 2013;19(21):3773-87. Review.

PMID:
23286438
7.

Inflammatory biomarkers and cardiovascular risk assessment. Current knowledge and future perspectives.

Moutzouri E, Tsimihodimos V, Tselepis AD.

Curr Pharm Des. 2013;19(21):3827-40. Review.

PMID:
23286437
8.

Effect of rosuvastatin monotherapy or in combination with fenofibrate or ω-3 fatty acids on lipoprotein subfraction profile in patients with mixed dyslipidaemia and metabolic syndrome.

Agouridis AP, Kostapanos MS, Tsimihodimos V, Kostara C, Mikhailidis DP, Bairaktari ET, Tselepis AD, Elisaf MS.

Int J Clin Pract. 2012 Sep;66(9):843-53. doi: 10.1111/j.1742-1241.2012.02972.x.

PMID:
22897461
9.

Combination therapies of DPP4 inhibitors and GLP1 analogues with insulin in type 2 diabetic patients: a systematic review.

Rizos EC, Ntzani EE, Papanas N, Tsimihodimos V, Mitrogianni Z, Maltezos E, Elisaf MS.

Curr Vasc Pharmacol. 2013 Nov;11(6):992-1000. Review.

PMID:
22724475
10.

A review of the role of apolipoprotein C-II in lipoprotein metabolism and cardiovascular disease.

Kei AA, Filippatos TD, Tsimihodimos V, Elisaf MS.

Metabolism. 2012 Jul;61(7):906-21. doi: 10.1016/j.metabol.2011.12.002. Epub 2012 Feb 2. Review.

PMID:
22304839
11.

Prediabetes: to treat or not to treat?

Moutzouri E, Tsimihodimos V, Rizos E, Elisaf M.

Eur J Pharmacol. 2011 Dec 15;672(1-3):9-19. doi: 10.1016/j.ejphar.2011.10.007. Epub 2011 Oct 12. Review.

PMID:
22020287
12.

Increased plasma visfatin concentration is a marker of an atherogenic metabolic profile.

Filippatos TD, Tsimihodimos V, Derdemezis CS, Gazi IF, Saougos V, Mikhailidis DP, Tselepis AD, Elisaf MS.

Nutr Metab Cardiovasc Dis. 2013 Apr;23(4):330-6. doi: 10.1016/j.numecd.2011.07.002. Epub 2011 Oct 2.

PMID:
21963513
13.

Effect of Plant Polyphenols on Adipokine Secretion from Human SGBS Adipocytes.

Derdemezis CS, Kiortsis DN, Tsimihodimos V, Petraki MP, Vezyraki P, Elisaf MS, Tselepis AD.

Biochem Res Int. 2011;2011:285618. doi: 10.1155/2011/285618. Epub 2011 Sep 22.

14.

The effects of rosuvastatin alone or in combination with fenofibrate or omega 3 fatty acids on inflammation and oxidative stress in patients with mixed dyslipidemia.

Agouridis AP, Tsimihodimos V, Filippatos TD, Dimitriou AA, Tellis CC, Elisaf MS, Mikhailidis DP, Tselepis AD.

Expert Opin Pharmacother. 2011 Dec;12(17):2605-11. doi: 10.1517/14656566.2011.591383. Epub 2011 Jun 29.

PMID:
21714585
15.

Editorial: secondary dyslipidemias.

Elisaf M, Tsimihodimos V.

Open Cardiovasc Med J. 2011;5:22-3. doi: 10.2174/1874192401105010022. Epub 2011 Feb 24. No abstract available.

16.

Dyslipidemia associated with chronic kidney disease.

Tsimihodimos V, Mitrogianni Z, Elisaf M.

Open Cardiovasc Med J. 2011;5:41-8. doi: 10.2174/1874192401105010041. Epub 2011 Feb 24.

17.

Lipoprotein glomerulopathy.

Tsimihodimos V, Elisaf M.

Curr Opin Lipidol. 2011 Aug;22(4):262-9. doi: 10.1097/MOL.0b013e328345ebb0. Review.

PMID:
21464714
18.

Combinations of ezetimibe with nonstatin drug regimens affecting lipid metabolism.

Agouridis AP, Filippatos TD, Tsimihodimos V, Elisaf MS.

Expert Rev Cardiovasc Ther. 2011 Mar;9(3):355-66. doi: 10.1586/erc.11.4. Review.

PMID:
21438815
19.

Aminoglycoside-induced nephrotoxicity studied by proton magnetic resonance spectroscopy of urine.

Tzovaras V, Tsimihodimos V, Kostara C, Mitrogianni Z, Elisaf M.

Nephrol Dial Transplant. 2011 Oct;26(10):3219-24. doi: 10.1093/ndt/gfr074. Epub 2011 Mar 3.

20.

High doses of rosuvastatin are superior to low doses of rosuvastatin plus fenofibrate or n-3 fatty acids in mixed dyslipidemia.

Agouridis AP, Tsimihodimos V, Filippatos TD, Tselepis AD, Elisaf MS.

Lipids. 2011 Jun;46(6):521-8. doi: 10.1007/s11745-011-3538-0. Epub 2011 Feb 15.

PMID:
21327725
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk